Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections

NCT07089186 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Hospital-acquired Bacterial Pneumonia (HABP)
Ventilator-associated Bacterial Pneumonia (VABP)
Complicated Intra-abdominal Infection (cIAI)
Complicated Urinary Tract Infection (cUTI)
Bloodstream Infection (BSI)

Interventions

DRUG: Meropenem and Pralurbactam
DRUG: Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)

Sponsor

Qilu Pharmaceutical Co., Ltd.